A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.9408 USD -2.58% Market Closed
Market Cap: 89.7m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Assertio Holdings Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Operating Expenses
-$104.9m
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
3%
Johnson & Johnson
NYSE:JNJ
Operating Expenses
-$36.5B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Expenses
-$24.9B
CAGR 3-Years
2%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Operating Expenses
-$29.4B
CAGR 3-Years
-11%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Expenses
-$26.7B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Operating Expenses
-$18.6B
CAGR 3-Years
-12%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
89.7m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.5439 USD
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Operating Expenses?
Operating Expenses
-104.9m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Operating Expenses amounts to -104.9m USD.

What is Assertio Holdings Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
3%

Over the last year, the Operating Expenses growth was -4%. The average annual Operating Expenses growth rates for Assertio Holdings Inc have been -4% over the past three years , 14% over the past five years , and 3% over the past ten years .

Back to Top